Spruce Biosciences Announces Data Presentation at the 18th International MPS Symposium
Spruce Biosciences will present long-term clinical data for its lead asset, tralesinidase alfa (TA-ERT), at the 18th International MPS Symposium in Florence, Italy. The presentation, led by Dr. Nicole Muschol, reports that long-term administration of TA-ERT results in profound and durable reduction of heparan sulfate and stabilization of cognitive function and cortical gray matter volume in patients with Sanfilippo Syndrome Type B.
Key figures
- Drug Name
- tralesinidase alfa (TA-ERT)
- Symposium
- 18th International MPS & Related Lysosomal Diseases Symposium
- Indication
- Sanfilippo Syndrome Type B (MPS IIIB)
- Presentation date
- June 6, 2026
- Presentation type
- Oral Poster Presentation
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.